NVCR logo

NovoCure Limited (NVCR)

$11.14

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on NVCR

Market cap

$1.30B

EPS

-1.06

P/E ratio

--

Price to sales

2.43

Dividend yield

--

Beta

1.093443

Price on NVCR

Previous close

$11.30

Today's open

$11.31

Day's range

$11.05 - $11.51

52 week range

$9.82 - $21.45

Profile about NVCR

CEO

Frank Leonard

Employees

1605

Headquarters

St. Helier, JE

Exchange

Nasdaq Global Select

Shares outstanding

116915959

Issue type

Common Stock

NVCR industries and sectors

Healthcare

Medical Equipment & Supplies

News on NVCR

JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that JAMA Network Open published the results of the prespecified secondary analysis of data from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel in patients with unresectable, locally advanced pancreatic adenocarcinoma. The PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel (GnP) as a first-line tre.

news source

Business Wire • Nov 13, 2026

news preview

FDA Rejects NovoCure's Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.

Mya is an investigational product in the Optune line. These wearable devices generate electric fields that disrupt cell division, ideally preventing the spread of cancer.

news source

The Motley Fool • Nov 10, 2026

news preview

Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket Approval (PMA) application for Optune Mya® for the treatment of adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation. The Not Approvable Letter indicates that the FDA determined that uncertainty around the degree of clinical benefit provided by Optune.

news source

Business Wire • Nov 9, 2026

news preview

Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock

Explore how NovoCure's (NVCR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

news source

Zacks Investment Research • Nov 2, 2026

news preview

NovoCure: 3 Key Takeaways for Long-Term Investors

NovoCure generated record third-quarter net revenue of $193 million. Active glioblastoma patients grew 11% year over year to 4,730.

news source

The Motley Fool • Nov 2, 2026

news preview

NovoCure Q3 Earnings Call Highlights

NovoCure NASDAQ: NVCR reported third-quarter 2026 net revenue of $193 million, up 16% from a year earlier, as growth in its Optune Gio business and an expanding launch of Optune Lua in Japan helped lift active patient counts to a record level. The company also raised its full-year revenue and adjusted EBITDA outlook while acknowledging commercial headwinds for its newer Optune Pax therapy in the United States.

news source

MarketBeat • Oct 29, 2026

news preview

NovoCure Limited (NVCR) Q3 2026 Earnings Call Transcript

NovoCure Limited ( NVCR ) Q3 2026 Earnings Call October 29, 2026 8:00 AM EDT Company Participants Adam Daney - Head of Investor Relations William Doyle - Executive Chairman Frank Leonard - CEO & Director Christoph Brackmann - Chief Financial Officer Uri Weinberg - Chief Innovation Officer & Chief Medical Officer Conference Call Participants Vijay Kumar - Evercore ISI Institutional Equities, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Jason Bednar - Piper Sandler & Co., Research Division Tanmay Patwardhan - JPMorgan Chase & Co. Kevin DeGeeter - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Good day, and welcome to the NovoCure Q3 2026 Earnings Call. [Operator Instructions] Please note, this call may be recorded.

news source

Seeking Alpha • Oct 29, 2026

news preview

Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) today reported financial results for the third quarter that ended September 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “Novocure's strong third quarter performance was driven by continued growth in our Optune Gio business and our growing portfolio of products launchin.

news source

Business Wire • Oct 29, 2026

news preview

NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates

NovoCure (NVCR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.33 per share a year ago.

news source

Zacks Investment Research • Oct 29, 2026

news preview

Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of Novocure's Tumor Treating Fields (TTFields) therapy with chemotherapy and VS-7375, Verastem's investigational oral, potent and selective KRAS G12D (ON/OFF) inhibitor, to treat locally advanced pancreatic cancer. “Meaningful progress has been made in the treatment of pancreatic cancer and we are prou.

news source

Business Wire • Oct 28, 2026

news preview

¹ Disclosures

Get started with M1

Invest in NovoCure Limited

Open an M1 investment account to buy and sell NovoCure Limited commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in NVCR on M1